Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer

Lung Cancer

Volumn 26, Issue 3, 1999, Pages 143-148

  Yano, Tokujiro ^a   Sugio, Kenji ^a   Yamazaki, Koji ^a   Kase, Shinichiro ^a   Yamaguchi, Masafumi ^a   Ondo, Kaoru ^a   Yoshino, Ichiro ^b   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Adoptive Immunotherapy; Interleukin 2; Lung cancer; Lymph node lymphocytes; Lymphokine activated killer cells; Stage I; Surgical adjuvant therapy

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SURVIVAL TIME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 0033491197     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00082-3     Document Type: Article

References (14)

1. Rosenberg S.A., Lotze M.T., Muul M.L., Leitman S., Chang A.E., Ettinghausen S.E. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New. Engl. J. Med. 313:1985;1485-1492.
2. Rosenberg S.A., Lotze M.T., Muul M.L., Chang A.E., Avis F.P., Leitman S. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New. Engl. J. Med. 316:1987;889-897.
3. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B. et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New. Engl. J. Med. 316:1987;898-905.
4. Clark J.W., Smith I.I. J.W., Steis R.G., Urba W.J., Crum E., Miller R. et al. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer. Res. 50:1990;7343-7350.
5. Dillman R.O., Oldham R.K., Tauer K.W., Orr D.W., Barth N.M., Blumenschein G. et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a national biotherapy study group trial. J. Clin. Oncol. 9:1991;1233-1240.
6. Kimura H., Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 80:1997;42-49.
7. Ratto G.B., Zino P., Mirabelli S., Minuti P., Aquilina R., Fantino G. et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer. 78:1996;244-251.
8. Yano T., Ishida T., Yoshino I., Murata M., Yasumoto K., Kimura G. et al. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Biotherapy. 3:1991;245-251.
9. Kato K., Yamada T., Kawahara K., Onda H., Asano T., Sugino H. et al. Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem. Biophys. Res. Commun. 130:1985;692-699.
10. Moriya N., Kato K., Suzuki N., Yamada T., Nishimura O. An enzyme-immunoassay for human interleukin-2. J. Immunoassay. 8:1987;131-143.
11. Yano T., Yasumoto K., Nomoto K. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer. Eur. J. Cancer. Clin. Oncol. 25:1989;201-208.
12. Murata M., Yano T., Togami M., Yasumoto K., Sugimachi K., Kimura G. et al. Development of a new culture system for human lymphokine-activated killer cells. J. Immunol. Methods. 129:1990;89-95.
13. Yano T., Murata M., Ishida T., Mitsudomi T., Kimura G., Sugimachi K. et al. Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. Cell. Immunol. 122:1989;578-584.
14. Yano T., Kimura G., Hara N., Ohta M., Sugimachi K., Nomoto K. Cytolytic profiles of interleukin-2-activated lymphocytes derived from various sites in lung cancer. Cancer. J. 4:1991;174-177.